Skip to main content
SpringerLink
Log in

Immunotyping and Quantification of Melanoma Tumor–Infiltrating Lymphocytes

  • Protocol
  • First Online:
Melanoma

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2265))

Abstract

The density of tumour-infiltrating lymphocytes (TILs) in melanoma is correlated with improved clinical prognosis; however, standardized TIL immunotyping and quantification protocols are lacking. Herein, we provide a review of the technologies being utilized for the immunotyping and quantification of melanoma TILs.

Max O. Meneveau and Zeyad T. Sahli are joint-first authors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Eerola A-K, Soini Y, Pääkkö P (2000) A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 6(5):1875–1881

    CAS  PubMed  Google Scholar 

  2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964

    Article  CAS  PubMed  Google Scholar 

  3. Robinson BD, Sica GL, Liu Y-F, Rohan TE, Gertler FB, Condeelis JS, Jones JG (2009) Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 15(7):2433–2441

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New Engl J Med 348(3):203–213

    Article  CAS  PubMed  Google Scholar 

  5. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30(21):2678–2683

    Article  PubMed  Google Scholar 

  6. Mihm MC Jr, Clemente CG, Cascinelli N (1996) Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Investig 74(1):43–47

    PubMed  Google Scholar 

  7. Amin MB, Edge SB, Greene F et al (eds) (2017) AJCC cancer staging manual, 8th edn. Springer, New York

    Google Scholar 

  8. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS (2013) Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. New Engl J Med 369(2):134–144

    Article  CAS  PubMed  Google Scholar 

  9. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E (2015) Nivolumab in previously untreated melanoma without BRAF mutation. New Engl J Med 372(4):320–330

    Article  CAS  PubMed  Google Scholar 

  10. LoRusso PM, Schalper K, Sosman J (2019) Targeted therapy and immunotherapy: emerging biomarkers in metastatic melanoma. Pigment Cell Melanoma Res 33(3):390–402

    Article  Google Scholar 

  11. Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KR, Zelterman D, Kluger HM, Rimm DL (2019) Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma. Clin Cancer Res 25(8):2442–2449

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Helgadottir H, Ghiorzo P, Van Doorn R, Puig S, Levin M, Kefford R, Lauss M, Queirolo P, Pastorino L, Kapiteijn E (2020) Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations. J Med Genet 57(5):316–321

    Article  CAS  PubMed  Google Scholar 

  13. Bayan C-A, Gartrell RD, Komatsubara KM, Pradhan JS, Marks DK, Lu Y, Borgardus M, Hasan SS, Lopez A, Hart TD (2018) Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma. J Clin Oncol 36(15_suppl):e21600. https://doi.org/10.1200/JCO.2018.36.15_suppl.e21600

    Article  Google Scholar 

  14. McGovern VJ, Mihm MC Jr, Bailly C, Booth JC, Clark WH Jr, Cochran AJ, Hardy E, Hicks J, Levene A, Lewis MG (1973) The classification of malignant melanoma and its histologic reporting. Cancer 32(6):1446–1457

    Article  CAS  PubMed  Google Scholar 

  15. Lee N, Zakka LR, Mihm MC Jr, Schatton T (2016) Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology 48(2):177–187

    Article  PubMed  Google Scholar 

  16. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Pénault-Llorca F (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259–271

    Article  CAS  PubMed  Google Scholar 

  17. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, Van De Vijver K, Estrada MV, Gonzalez-Ericsson PI (2017) Assessing tumor infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol 24(5):235–251

    Article  PubMed  PubMed Central  Google Scholar 

  18. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, Van De Vijver K, Estrada MV, Gonzalez-Ericsson PI (2017) Assessing tumor infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 24(6):311–335

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kononen J, Bubendorf L, Kallionimeni A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallionimeni OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847

    Article  CAS  PubMed  Google Scholar 

  20. Fedor HL, De Marzo AM (2005) Practical methods for tissue microarray construction. In: Su GH (ed) Pancreatic cancer. Methods in molecular medicine, vol 103. Humana Press, New Jersey

    Google Scholar 

  21. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL (2012) Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72(5):1070–1080

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Eskaros AR, Egloff SAA, Boyd KL, Richardson JE, Hyndman ME, Zijlstra A (2017) Larger core size has superior technical and analytical accuracy in bladder tissue microarray. Lab Investig 97(3):335–342

    Article  CAS  PubMed  Google Scholar 

  23. Anagnostou VK, Lowery FJ, Syrigos KN, Cagle PT, Rimm DL (2010) Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core? Arch Pathol Lab Med 134(4):613–619

    Article  PubMed  Google Scholar 

  24. Stack EC, Wang C, Roman KA, Hoyt CC (2014) Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 70(1):46–58

    Article  CAS  PubMed  Google Scholar 

  25. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. New Engl J Med 353(25):2654–2666

    Article  PubMed  Google Scholar 

  26. Halse H, Colebatch A, Petrone P, Henderson M, Mills J, Snow H, Westwood J, Sandhu S, Raleigh J, Behren A (2018) Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma. Sci Rep 8(1):1–14

    Article  CAS  Google Scholar 

  27. Berndt U, Philipsen L, Bartsch S, Hu Y, Röcken C, Bertram W, Hämmerle M, Rösch T, Sturm A (2010) Comparative multi-epitope-ligand-cartography reveals essential immunological alterations in Barrett's metaplasia and esophageal adenocarcinoma. Mol Cancer 9(1):177. https://doi.org/10.1186/1476-4598-9-177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Eckhardt J, Ostalecki C, Kuczera K, Schuler G, Pommer AJ, Lechmann M (2013) Murine whole-organ immune cell populations revealed by multi-epitope-ligand cartography. J Histochem Cytochem 61(2):125–133

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Glass G, Papin JA, Mandell JW (2009) SIMPLE: a sequential immunoperoxidase labeling and erasing method. J Histochem Cytochem 57(10):899–905

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Giesen C, Wang HA, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, Schüffler PJ, Grolimund D, Buhmann JM, Brandt S, Varga Z, Wild PJ, Günther D, Bodenmiller B (2014) Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods 11(4):417–422

    Article  CAS  PubMed  Google Scholar 

  31. Saka SK, Wang Y, Kishi JY, Zhu A, Zeng Y, Xie W, Kirli K, Yapp C, Cicconet M, Beliveau BJ, Lapan SW, Yin S, Lin M, Boyden ES, Kaeser PS, Pihan G, Church GM, Yin P (2019) Immuno-SABER enables highly multiplexed and amplified protein imaging in tissues. Nat Biotechnol 37(9):1080–1090

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Goltsev Y, Samusik N, Kennedy-Darling J, Bhate S, Hale M, Vazquez G, Black S, Nolan GP (2018) Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. Cell 174(4):968–981.e15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Leick KM, Pinczewski J, Mauldin IS, Young SJ, Deacon DH, Woods AN, Bosenberg MW, Engelhard VH, Slingluff CL (2019) Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors. Cancer Immunol Immunother 68(7):1121–1132

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Stowman AM, Hickman AW, Mauldin IS, Mahmutovic A, Gru AA, Slingluff CL Jr (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28(3):237–245

    Article  PubMed  PubMed Central  Google Scholar 

  35. Melssen MM, Olson W, Wages NA, Capaldo BJ, Mauldin IS, Mahmutovic A, Hutchison C, Melief CJM, Bullock TN, Engelhard VH, Slingluff CL (2018) Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma. OncoImmunology 7(10):e1490855. https://doi.org/10.1080/2162402X.2018.1490855

    Article  PubMed  PubMed Central  Google Scholar 

  36. Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, Saenger YM (2018) Quantitative analysis of immune infiltrates in primary melanoma. Cancer Immunol Res 6(4):481–493

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Parra ER, Uraoka N, Jiang M, Cook P, Gibbons D, Forget M-A, Bernatchez C, Haymaker C, Wistuba II, Rodriguez-Canales J (2017) Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Sci Rep 7(1):1–11

    Article  CAS  Google Scholar 

  38. Huang W, Hennrick K, Drew S (2012) A colorful future for quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Am J Clin Pathol 138(suppl_2):A241–A241

    Article  Google Scholar 

  39. Kowalczyk D, Skorupski W, Kwias Z, Nowak J (1997) Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br J Urol 80(4):543–547

    Article  CAS  PubMed  Google Scholar 

  40. Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL (2008) Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 180(5):2967–2980

    Article  CAS  PubMed  Google Scholar 

  41. Whitford P, Mallon EA, George WD, Campbell AM (1990) Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br J Cancer 62(6):971–975. https://doi.org/10.1038/bjc.1990.419

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Woroniecka K, Chongsathidkiet P, Elsamadicy A, Farber H, Cui X, Fecci PE (2018) Flow cytometric identification of tumor-infiltrating lymphocytes from glioblastoma. In: Placantonakis D (ed) Glioblastoma methods in molecular biology, vol 1741. Humana Press, New York

    Google Scholar 

  43. Bandura DR, Baranov VI, Ornatsky OI, Antonov A, Kinach R, Lou X, Pavlov S, Vorobiev S, Dick JE, Tanner SD (2009) Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem 81(16):6813–6822

    Article  CAS  PubMed  Google Scholar 

  44. Brooks D, Gadalla R, Noamani B, Macleod B, Dickson R, Guo M, Xu W, Lukhele S, Elsaesser H, Razak A (2019) Validation of CyTOF against flow cytometry for immunological studies and monitoring of human cancer clinical trials. Front Oncol 9:415

    Article  PubMed  PubMed Central  Google Scholar 

  45. Sumatoh HR, Teng KWW, Cheng Y, Newell EW (2017) Optimization of mass cytometry sample cryopreservation after staining. Cytometry A 91(1):48–61

    Article  CAS  PubMed  Google Scholar 

  46. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV (2015) Combination therapy with anti–CTLA-4 and anti–PD-1 leads to distinct immunologic changes in vivo. J Immunol 194(3):950–959

    Article  CAS  PubMed  Google Scholar 

  47. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang N-AAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe’er D, Allison JP (2017) Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170(6):1120–1133.e17

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Hiniker SM, Reddy SA, Maecker HT, Subrahmanyam PB, Rosenberg-Hasson Y, Swetter SM, Saha S, Shura L, Knox SJ (2016) A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. Int J Radiat Oncol Biol Phys 96(3):578–588

    Article  PubMed  PubMed Central  Google Scholar 

  49. Wistuba-Hamprecht K, Martens A, Weide B, Teng KWW, Zelba H, Guffart E, Chen J, Garbe C, Newell EW, Larbi A (2017) Establishing high dimensional immune signatures from peripheral blood via mass cytometry in a discovery cohort of stage IV melanoma patients. J Immunol 198(2):927–936

    Article  CAS  PubMed  Google Scholar 

  50. Takeuchi Y, Tanemura A, Tada Y, Katayama I, Kumanogoh A, Nishikawa H (2018) Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. Int Immunol 30(1):13–22

    Article  CAS  PubMed  Google Scholar 

  51. Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B (2018) High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med 24(2):144–153

    Article  CAS  PubMed  Google Scholar 

  52. Hogan SA, Levesque MP, Cheng PF (2018) Melanoma immunotherapy: next-generation biomarkers. Front Oncol 8:178

    Article  PubMed  PubMed Central  Google Scholar 

  53. Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C, Depil S (2019) Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol 10:168

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Clark WH Jr, Elder DE, Guerry D IV, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81(24):1893–1904

    Article  PubMed  Google Scholar 

  55. Busam KJ, Antonescu CR, Marghoob AA, Nehal KS, Sachs DL, Shia J, Berwick M (2001) Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma: a study of interobserver agreement. Am J Clin Pathol 115(6):856–860

    Article  CAS  PubMed  Google Scholar 

  56. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7):1303–1310

    Article  CAS  PubMed  Google Scholar 

  57. Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F (2016) Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. Hum Pathol 57:116–125

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu Y-L, Adams S, Darvishian F, Berman R, Shapiro R, Pavlick AC (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A 106(48):20429–20434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Obeid JM, Erdag G, Smolkin ME, Deacon DH, Patterson JW, Chen L, Bullock TN, Slingluff CL (2016) PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: correlation with tumor-infiltrating immune cells and clinical outcome. Onco Targets Ther 5(11):e1235107

    Google Scholar 

  60. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G (2012) Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10(1):205

    Article  PubMed  PubMed Central  Google Scholar 

  61. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman W-H, Pages F (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29(6):610–618

    Article  PubMed  Google Scholar 

  62. Galon J, Mlecnik B, Marliot F, Ou F-S, Bifulco CB, Lugli A, Zlobec I, Rau TT, Hartmann A, Masucci GV (2016) Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: results of a worldwide consortium-based analysis of 1,336 patients. J Clin Oncol 34(15_suppl):3500. https://doi.org/10.1200/JCO.2016.34.15_suppl.3500

    Article  Google Scholar 

  63. Chen H, Xia B, Zheng T, Lou G (2020) Immunoscore system combining CD8 and PD-1/PD-L1: a novel approach that predicts the clinical outcomes for cervical cancer. Int J Biol Markers 35(1):65–73

    Article  CAS  PubMed  Google Scholar 

  64. Selvi I, Demirci U, Bozdogan N, Basar H (2020) The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results. Int Urol Nephrol 52(1):21–34

    Article  CAS  PubMed  Google Scholar 

  65. Baxevanis CN, Sofopoulos M, Fortis SP, Perez SA (2019) The role of immune infiltrates as prognostic biomarkers in patients with breast cancer. Cancer Immunol Immunother 68(10):1671–1680

    Article  CAS  PubMed  Google Scholar 

  66. Hynes CF, Kwon DH, Vadlamudi C, Lofthus A, Iwamoto A, Chahine JJ, Desale S, Margolis M, Kallakury BV, Watson TJ (2018) Programmed death ligand 1: a step toward immunoscore for esophageal cancer. Ann Thorac Surg 106(4):1002–1007

    Article  PubMed  Google Scholar 

  67. Zheng X, Song X, Shao Y, Xu B, Hu W, Zhou Q, Chen L, Zhang D, Wu C, Jiang J (2018) Prognostic role of tumor-infiltrating lymphocytes in esophagus cancer: a meta-analysis. Cell Physiol Biochem 45(2):720–732

    Article  CAS  PubMed  Google Scholar 

  68. Tahkola K, Leppänen J, Ahtiainen M, Väyrynen J, Haapasaari K-M, Karttunen T, Kellokumpu I, Helminen O, Böhm J (2019) Immune cell score in pancreatic cancer—comparison of hotspot and whole-section techniques. Virchows Arch 474(6):691–699

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Max O. Meneveau and Zeyad T. Sahli are joint-first authors.

Author information

Authors and Affiliations

  1. Department of Surgery, The University of Virginia Health System, Charlottesville, VA, USA

    Max O. Meneveau, Zeyad T. Sahli, Kevin T. Lynch, Ileana S. Mauldin & Craig L. Slingluff Jr.

Authors
  1. Max O. Meneveau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zeyad T. Sahli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kevin T. Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ileana S. Mauldin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Craig L. Slingluff Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Craig L. Slingluff Jr. .

Editor information

Editors and Affiliations

  1. Department of Biology, Hampden-Sydney College, Hampden-Sydney, VA, USA

    Kristian M. Hargadon

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Meneveau, M.O., Sahli, Z.T., Lynch, K.T., Mauldin, I.S., Slingluff, C.L. (2021). Immunotyping and Quantification of Melanoma Tumor–Infiltrating Lymphocytes. In: Hargadon, K.M. (eds) Melanoma. Methods in Molecular Biology, vol 2265. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1205-7_36

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-1205-7_36

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-1204-0

  • Online ISBN: 978-1-0716-1205-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation